Mice with liver composed of human hepatocytes as an animal model for drug testing

Current Drug Discovery Technologies

Volumn 9, Issue 1, 2012, Pages 63-76

  Yoshizato, Katsutoshi ^a,b   Tateno, Chise ^a   Utoh, Rie ^c  

^a PhoenixBio   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Growth hormone; Hepatic stellate cells; Hepatitis viruses; In vivo drug testing; Liver regeneration; Liver steatosis; Mice with human liver; TGF signaling

Indexed keywords

ALISPORIVIR; ALVESPIMYCIN; ANTIVIRUS AGENT; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; CYTOCHROME P450; GROWTH HORMONE; LAMIVUDINE; SUPPRESSOR OF CYTOKINE SIGNALING 2; THERMOZYMOCIDIN; TRANSCRIPTION FACTOR MASH1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANTIVIRAL RESISTANCE; CELL INTERACTION; CELL PROLIFERATION; DNA SYNTHESIS; DOWN REGULATION; DRUG ABSORPTION; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SCREENING; FATTY LIVER; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS VIRUS; HISTOPATHOLOGY; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; LIVER HYPERPLASIA; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; UPREGULATION; VIREMIA; VIRUS REPLICATION;

ANIMALS; DRUG DESIGN; HEPATOCYTES; HUMANS; LIVER; MICE; MODELS, ANIMAL; SPECIES SPECIFICITY; TRANSPLANTATION CHIMERA;

EID: 84858191432     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312799304570     Document Type: Review

References (82)

1. Nakanishi Y, Matsushita A, Matsuno K, et al. Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkey. Drug Metab Pharmacokinet 2011; 26(3): 288-94.
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-21.
3. Mercer DF, Schiller DE, Elliott J, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-33. (Pubitemid 32756430)
4. Dandri M, Burda MR, Török E, et al. Repopulation of mouse liver with human hepatocytes and In vivo infection with hepatitis B virus. Hepatology 2001; 33: 981-8. (Pubitemid 32246649)
5. Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005; 42: 1046-54. (Pubitemid 43112671)
6. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-12. (Pubitemid 39129297)
7. Yoshizato K, Tateno C. A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans. PPAR Res 2009: 2009: 476217.
8. Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2009; 5: 1435-46.
9. Utoh R, Tateno C, Kataoka M, et al. Hepatic hyperplasia associated with discordant xenogeneic parenchymal-nonparenchymal interactions in human hepatocyte-repopulated mice. Am J Pathol 2010; 177: 654-65.
10. Tateno C, Kataoka M, Utoh R, et al. Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver. Endocrinology 2011; 152: 1479-91.
11. Baratta JL, Ngo A, Lopez B, Kasabwalla N, Longmuir KJ, Robertson RT. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol 2009; 131: 713-26.
12. Wake K. Functional heterogeneity of liver tissue: from cell lineage diversity to sublobular compartment. In sinusoidal structure and dynamics (Ed. Vidal-Vanaclocha F). Springer and R.G.Landes Company 1997, 57-67.
13. Rhim JA, Sandgren EP, Palmiter RD, Brinster RL. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci USA 1995; 92: 4942-6.
14. Wack KE, Ross MA, Zegarra V, Sysko LR, Watkins SC, Stolz DB. Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. Hepatology 2001; 33: 363-78. (Pubitemid 32119025)
15. Martinez-Hernandez A, Delgado FM, Amenta PS. The extracellular matrix in hepatic regeneration. Localization of collagen types I, III, IV, laminin, and fibronectin. Lab Invest 1991; 64: 157-66.
16. Koniaris LG, McKillop IH, Schwartz SI, Zimmers TA. Liver regeneration. J Am Coll Surg 2003; 197: 634-59. (Pubitemid 38223851)
17. Yoshizato K, Tateno C, Utoh R. The Mechanism of liver size control in mannmals: a novel animal study. Int J Des Nat Ecodyn 2009; 4: 123-42.
18. Russell WE. Transforming growth factor beta (TGF-beta) inhibits hepatocyte DNA synthesis independently of EGF binding and EGF receptor autophosphorylation. J Cell Physiol 1988; 135: 253-61.
19. Romero-Gallo J, Sozmen EG, Chytil A, et al. Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene 2005; 24: 3028-41. (Pubitemid 40675534)
20. Oe S, Lemmer ER, Conner EA, et al. Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology 2004; 40: 1098-105. (Pubitemid 39425565)
21. Ten Dijke P, Miyazono K, Heldin CH. Signaling via heterooligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol 1996; 8: 139-45. (Pubitemid 26109085)
22. Veldhuis JD, Roemmich JN, Richmond EJ, et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005; 26: 114-46. (Pubitemid 40209389)
23. Piwien-Pilipuk G, Huo JS, Schwartz J. Growth hormone signal transduction. J Pediatr Endocrinol Metab 2002; 15: 771-86. (Pubitemid 34704828)
24. Wei Y, Rhani Z, Goodyer CG. Characterization of growth hormone receptor messenger ribonucleic acid variants in human adipocytes. J Clin Endocrinol Metab 2006; 91: 1901-8.
25. Souza SC, Frick GP, Wang X, Kopchick JJ, Lobo RB, Goodman HM. A single arginine residue determines species specificity of the human growth hormone receptor. Proc Natl Acad Sci USA 1995: 14; 92: 959-63.
26. Castellano G, Affuso F, Conza PD, Fazio S. The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev 2009; 5: 203-15.
27. Masumoto N, Tateno C, Tachibana A, et al. GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver. J Endocrinol 2007; 194: 529-37. (Pubitemid 47471221)
28. Asakawa K, Hizuka N, Takano K, et al. Human growth hormone stimulates liver regeneration in rats. J Endocrinol Invest 1989; 12: 343-7. (Pubitemid 19155181)
29. Bucher NL, Swaffield MN, Ditroia JF. The influence of age upon the incorporation of thymidien-2-C14 into the DNA of regenerating rat liver. Cancer Res 1964; 24: 509-12.
30. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6. (Pubitemid 20209464)
31. Krupczak-Hollis K, Wang X, Dennewitz MB, Costa RH. Growth hormone stimulates proliferation of old-aged regenerating liver through forkhead box m1b. Hepatology 2003; 38: 1552-62. (Pubitemid 37466981)
32. Pennisi PA, Kopchick JJ, Thorgeirsson S, LeRoith D, Yakar S. Role of growth hormone (GH) in liver regeneration. Endocrinology 2004; 145: 4748-55. (Pubitemid 39281469)
33. Sangiao-Alvarellos S, Vázquez MJ, Varela L, et al. Central ghrelin regulates peripheral lipid metabolism in a growth hormoneindependent fashion. Endocrinology 2009; 150: 4562-74.
34. Hu Y, Wang T, Stormo GD, Gordon JI. RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites. Proc Natl Acad Sci USA 2004; 101: 5559-64. (Pubitemid 38488831)
35. Martinez-Jimenez CP, Kyrmizi I, Cardot P, Gonzalez FJ, Talianidis I. Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. Mol Cell Biol 2010; 30: 565-77.
36. Tollet-Egnell P, Flores-Morales A, Stavréus-Evers A, Sahlin L, Norstedt G. Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology 1999; 140: 3693-704. (Pubitemid 30645425)
37. Adams TE, Hansen JA, Starr R, Nicola NA, Hilton DJ, Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem 1998; 273: 1285-7. (Pubitemid 28133642)
38. Cui Y, Hosui A, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 2007; 46: 504-13. (Pubitemid 47344786)
39. Rico-Bautista E, Greenhalgh CJ, Tollet-Egnell P, et al. Suppressor of cytokine signaling-2 deficiency induces molecular and metabolic changes that partially overlap with growth hormone-dependent effects. Mol Endocrinol 2005; 19: 781-93. (Pubitemid 40349448)
40. Vidal OM, Merino R, Rico-Bautista E, et al. In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol 2007; 21: 293-311. (Pubitemid 46041708)
41. Chen L, Shen YH, Wang X, et al. Human prolyl-4-hydroxylase alpha(I) transcription is mediated by upstream stimulatory factors. J Biol Chem 2006; 281: 10849-55. (Pubitemid 43855507)
42. Lasher CD, Rajagopalan P, Murali TM. Discovering networks of perturbed biological processes in hepatocyte cultures. PLoS One 2011; 6: 15247.
43. Zheng XL, Wong NC. Cyclosporin A inhibits apolipoprotein AI gene expression. J Mol Endocrinol 2006; 37: 367-73. (Pubitemid 44615305)
44. Bailly-Maitre B, Bard-Chapeau E, Luciano F, et al. Mice lacking bi-1 gene show accelerated liver regeneration. Cancer Res 2007; 67: 1442-50. (Pubitemid 46383369)
45. Whatmore AJ, Patel L, Clayton PE. A pilot study to evaluate gene expression profiles in peripheral blood mononuclear cells (PBMCs) from children with GH deficiency and Turner syndrome in response to GH treatment. Clin Endocrinol (Oxf) 2009; 70: 429-34.
46. Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 2009; 4: 6796.
47. Studler JM, Glowinski J, Lévi-Strauss M. An abundant mRNA of the embryonic brain persists at a high level in cerebellum, hippocampus and olfactory bulb during adulthood. Eur J Neurosci 1993; 5: 614-23. (Pubitemid 23187818)
48. Leung JK, Cases S, Vu TH. P311 functions in an alternative pathway of lipid accumulation that is induced by retinoic acid. J Cell Sci 2008; 121: 2751-8.
49. Paparini A, Impagnatiello F, Pistilli A, et al. Identification of candidate genes and expression profiles, as doping biomarkers. Ann Ig 2007; 19: 303-14.
50. Lin HY, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology 2008; 47: 1924-35.
51. Li KK, Pang JC, Ching AK, et al. miR-124 is frequently downregulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol 2009; 40: 1234-43.
52. Merino DM, Ma DW, Mutch DM. Genetic variation in lipid desaturases and its impact on the development of human disease. Lipids Health Dis 2010; 18; 9: 63.
53. Zhu J, Gardner J, Pullinger CR, Kane JP, Thompson JF, Francone OL. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. J Lipid Res 2009; 50: 1330-9.
54. Camarota LM, Chapman JM, Hui DY, Howles PN. Carboxyl ester lipase cofractionates with scavenger receptor BI in hepatocyte lipid rafts and enhances selective uptake and hydrolysis of cholesteryl esters from HDL3. J Biol Chem 2004; 279: 27599-606. (Pubitemid 38812601)
55. Huang R, Silva RA, Jerome WG, et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011; 8: 416-22.
56. Wang C, Yan R, Luo D, Watabe K, Liao DF, Cao D. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 2009; 284: 26742-8.
57. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 1993; 91: 2185-93. (Pubitemid 23141495)
58. Targher G, Bertolini L, Scala L, et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007; 30: 31-2.
59. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5: 149-54. (Pubitemid 40378745)
60. Matsuzawa N, Takamura T, Kurita S, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46: 1392-403. (Pubitemid 350155521)
61. Ishii M, Yoshioka Y, Ishida W, et al. Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects. Tohoku J Exp Med 2005; 206: 23-30. (Pubitemid 40568160)
62. Komiya Y, Katayama K, Yugi H, et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48: 286-94.
63. Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006; 50: 3867-74. (Pubitemid 44684905)
64. Tsuge M, Hiraga N, Akiyama R, et al. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J Gen Virol 2010; 91: 1854-64.
65. Sugiyama M, Tanaka Y, Kurbanov F, et al. Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 2009; 136: 652-62.
66. Umehara T, Sudoh M, Yasui F, et al. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 2006; 346: 67-73. (Pubitemid 43884734)
67. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 2007; 353: 882-8. (Pubitemid 46080379)
68. Inoue K, Umehara T, Ruegg UT, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007; 45: 921-8. (Pubitemid 46631561)
69. Kamiya N, Iwao E, Hiraga N, et al. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J Gen Virol 2010; 91: 1668-77.
70. Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol 2011; 54: 872-8.
71. Takano T, Tsukiyama-Kohara K, Hayashi M, et al. Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes. J Hepatol 2011; 55(3): 512-21.
72. Katoh M, Matsui T, Okumura H, et al. Expression of human cytochrome P450 in chimeric mice with humanized liver. Drug Metab Dispos 2004; 32: 1402-10. (Pubitemid 39564560)
73. Katoh M, Matsui T, Okumura H, et al. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 2005; 33: 754-63. (Pubitemid 40686628)
74. Katoh M, Matsui T, Okumura H, et al. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 2005; 33: 1333-40. (Pubitemid 41196976)
75. Kitamura S, Nitta K, Tayama Y, et al. Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide In vivo and In vitro in chimeric mice with humanized liver. Drug Metab Dispos 2008; 36: 1202-5. (Pubitemid 351929332)
76. Katoh M, Sawada T, Soeno Y, et al. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 2007; 96: 428-37. (Pubitemid 46363572)
77. Okumura H, Katoh M, Sawada T, et al. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 2007; 97: 533-8. (Pubitemid 47073867)
78. Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin In vivo and In vitro in chimeric mice with humanized liver. Drug Metab Dispos 2008; 36: 2429-33.
79. Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S. Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab. Pharmacokinet 2009; 24: 153-60.
80. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-9.
81. Yamasaki C, Kataoka M, Kato Y, et al. In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 2010; 25: 539-50.
82. Kamimura H, Nakada N, Suzuki K, et al. Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 2010; 25: 223-35.